Full Text View
Tabular View
No Study Results Posted
Related Studies
Vaccine Therapy and QS21 in Treating Patients With Metastatic Breast Cancer
This study is currently recruiting participants.
Verified by National Cancer Institute (NCI), December 2008
First Received: May 3, 2007   Last Updated: April 8, 2009   History of Changes
Sponsors and Collaborators: Memorial Sloan-Kettering Cancer Center
National Cancer Institute (NCI)
Information provided by: National Cancer Institute (NCI)
ClinicalTrials.gov Identifier: NCT00470574
  Purpose

RATIONALE: Vaccines may help the body build an effective immune response to kill tumor cells. Giving vaccine therapy together with QS21 may cause a stronger immune response and kill more tumor cells.

PURPOSE: This clinical trial is studying the side effects and how well giving vaccine therapy together with QS21 works in treating patients with metastatic breast cancer.


Condition Intervention
Breast Cancer
Biological: QS21
Biological: sialyl Lewisª-keyhole limpet hemocyanin conjugate vaccine
Other: immunoenzyme technique
Other: immunologic technique
Other: laboratory biomarker analysis

Genetics Home Reference related topics: breast cancer
MedlinePlus related topics: Breast Cancer Cancer
Drug Information available for: QS 21
U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment
Official Title: Pilot Study of Immunization of High Risk Breast Cancer Patients With a Sialyl Lewisª -Keyhole Limpet Hemocyanin Conjugate Plus the Immunological Adjuvant QS-21

Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Safety [ Designated as safety issue: Yes ]
  • Immune response [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Presence of circulating tumor cells [ Designated as safety issue: No ]

Estimated Enrollment: 23
Study Start Date: March 2007
Estimated Primary Completion Date: March 2010 (Final data collection date for primary outcome measure)
Detailed Description:

OBJECTIVES:

Primary

  • Determine the safety of sialyl Lewisª -keyhole limpet hemocyanin conjugate vaccine and QS21 immunoadjuvant in patients with metastatic breast cancer.
  • Determine the IgG and IgM antibody response to this regimen in these patients.
  • Determine the proportion of breast cancer cells expressing this antigen in these patients.

Secondary

  • Monitor the presence of circulating tumor cells prior to, during, and after this regimen in these patients.

OUTLINE: Patients receive sialyl Lewisª -keyhole limpet hemocyanin conjugate vaccine subcutaneously (SC) and QS21 immunoadjuvant SC once in weeks 1, 2, 3, 7, and 19 in the absence of disease progression or unacceptable disease.

Blood samples are collected periodically and evaluated for circulating tumor cells and reactivity against sialyl Lewisª antigen in ELISA and/or immunoprecipitation-western blot assays.

After completion of study treatment, patients are followed every 3 months.

PROJECTED ACCRUAL: A total of 23 patients will be accrued for this study.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

DISEASE CHARACTERISTICS:

  • Histologically confirmed stage IV breast cancer meeting 1 of the following criteria:

    • No evidence of disease
    • Stable disease on hormonal therapy

      • Stable disease must be present for ≥ 2 months and include < 30% decrease or < 20% increase in the sum of the longest diameter of target lesion
      • No new target lesions or unequivocal progression of non-target lesions
      • Elevation in the CA 153 (BR2729) or CEA values allowed
  • Hormone receptor status not specified

PATIENT CHARACTERISTICS:

  • Female or male
  • Menopausal status not specified
  • Karnofsky performance status 80-100%
  • Lymphocyte count ≥ 500/mm³
  • WBC ≥ 3,000/mm³
  • Creatinine ≤ 1.5 times upper limit of normal (ULN)
  • AST ≤ 1.5 times ULN
  • Alkaline phosphatase ≤ 1.5 times ULN
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • No history of allergy to seafood
  • No NYHA class III-IV cardiac disease
  • No other active cancers except basal cell or squamous cell carcinoma of the skin
  • No active infection requiring antibiotic treatment
  • No known history of immunodeficiency or autoimmune disease

PRIOR CONCURRENT THERAPY:

  • See Disease Characteristics
  • At least 4 weeks since prior chemotherapy
  • At least 4 weeks since prior radiotherapy
  • At least 4 weeks since prior surgery
  • At least 6 weeks since prior immunotherapy
  • No prior sialyl Lewisª antigen
  • No concurrent immunosuppressive medications (i.e., corticosteroids)
  • Concurrent hormonal therapy allowed
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00470574

Locations
United States, New York
Memorial Sloan-Kettering Cancer Center Recruiting
New York, New York, United States, 10065
Contact: Teresa Ann Gilewski, MD     646-888-4557        
Sponsors and Collaborators
Memorial Sloan-Kettering Cancer Center
Investigators
Principal Investigator: Teresa Ann Gilewski, MD Memorial Sloan-Kettering Cancer Center
Principal Investigator: Maura N. Dickler, MD Memorial Sloan-Kettering Cancer Center
  More Information

Additional Information:
No publications provided

Study ID Numbers: CDR0000542903, MSKCC-06156
Study First Received: May 3, 2007
Last Updated: April 8, 2009
ClinicalTrials.gov Identifier: NCT00470574     History of Changes
Health Authority: Unspecified

Keywords provided by National Cancer Institute (NCI):
recurrent breast cancer
stage IV breast cancer
male breast cancer

Study placed in the following topic categories:
Immunologic Factors
Skin Diseases
Breast Neoplasms, Male
Adjuvants, Immunologic
Breast Neoplasms
Breast Cancer, Male
QS 21
Keyhole-limpet hemocyanin
Breast Diseases
Recurrence

Additional relevant MeSH terms:
Neoplasms
Neoplasms by Site
Immunologic Factors
Skin Diseases
Physiological Effects of Drugs
Adjuvants, Immunologic
Breast Neoplasms
QS 21
Keyhole-limpet hemocyanin
Pharmacologic Actions
Breast Diseases

ClinicalTrials.gov processed this record on May 07, 2009